V3020

antibody from NSJ Bioreagents

Targeting: CD59 16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

V3020

Provider

NSJ Bioreagents

Product name

CD59 Antibody

Antibody type

Monoclonal

Antigen

Stimulated human leukocytes were used as the immunogen for the CD59 antibody.

Description

PEG precipitated antibody

Reactivity

Human

Host

Mouse

Conjugate

Unconjugated

Antibody clone number

193-27

Vial size

20 µg, 100 µg (with sodium azide), 100 µg (without sodium azide), 7 ml (prediluted for IHC use, if applicable)

Storage

Store the CD59 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

References

Submitted references

Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.

Ravindranath NM, Shuler C
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 2007 Feb;103(2):231-9

---

Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas.

Ravindranath NM, Shuler C
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2006 Oct;35(9):560-7

---

Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species.

Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Esteve J, Campo E, Colomer D, Montserrat E
Blood 2001 Nov 1;98(9):2771-7